<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arab J Urol</journal-id><journal-id journal-id-type="iso-abbrev">Arab J Urol</journal-id><journal-title-group><journal-title>Arab Journal of Urology</journal-title></journal-title-group><issn pub-type="ppub">2090-598X</issn><issn pub-type="epub">2090-5998</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26413337</article-id><article-id pub-id-type="pmc">4561918</article-id><article-id pub-id-type="publisher-id">S2090-598X(15)00017-0</article-id><article-id pub-id-type="doi">10.1016/j.aju.2015.01.004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The clinical significance of HER2 protein amplification/expression in urinary bladder lesion</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hammam</surname><given-names>Olfat</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Nour</surname><given-names>Hani H.</given-names></name><email>hani_nour@hotmail.com</email><xref rid="af010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Mosaad</surname><given-names>Maha</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Akl</surname><given-names>Maha</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Khalil</surname><given-names>Heba</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>al Ganzory</surname><given-names>Hossam</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Hindawi</surname><given-names>Ali</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib></contrib-group><aff id="af005"><label>a</label>Pathology Department, Theodor Bilharz Research Institute, Giza Egypt</aff><aff id="af010"><label>b</label>Urology Department, Theodor Bilharz Research Institute, Giza Egypt</aff><aff id="af015"><label>c</label>Pathology Department, Kasr El Aini School of Medicine, Cairo University, Egypt</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. Tel.: +20 1111000 191. <email>hani_nour@hotmail.com</email></corresp><fn id="fn1"><label>1</label><p>Urology Department, Stanford University, CA, USA.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>3</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>18</day><month>3</month><year>2015</year></pub-date><volume>13</volume><issue>2</issue><fpage>146</fpage><lpage>152</lpage><history><date date-type="received"><day>13</day><month>8</month><year>2014</year></date><date date-type="rev-recd"><day>11</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Arab Association of Urology. Production and hosting by Elsevier B.V.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Arab Association of Urology</copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract><sec><title>Objective</title><p>To evaluate HER2 oncoprotein expression by both immunohistochemical (IHC) staining and fluorescence <italic>in situ</italic> hybridisation (FISH) in different benign and malignant bladder lesions, and the effect of bilharzial infestation on this expression.</p></sec><sec><title>Patients and methods</title><p>In a prospective controlled study, 72 patients were classified into a control group, and groups with cystitis, urothelial carcinoma, and squamous cell carcinoma (SCC). HER2 was detected using standard IHC staining and FISH in all groups. The correlation of HER2 expression with tumour type, stage and grade in relation to normal urothelium and cystitis was assessed. The effect of schistosomal infestation was evaluated.</p></sec><sec><title>Results</title><p>HER2 expression was statistically significantly higher in patients with malignant lesions than in the other groups, and in high-stage and -grade tumours than in low-stage and -grade tumours. The use of FISH increased the detection of HER2-positive tumours. Schistosomal infestation did not affect HER2 expression in patients with transitional cell carcinoma.</p></sec><sec><title>Conclusion</title><p>High-stage and -grade bladder malignancies expressed HER2 much more than did benign lesions. FISH is more sensitive for detecting HER2 expression. The treatment of HER2-positive tumours might benefit from novel targeted-treatment protocols.</p></sec></abstract><kwd-group><title>Abbreviations</title><kwd>IHC, immunohistochemical</kwd><kwd>FISH, fluorescence <italic>in situ</italic> hybridisation</kwd><kwd>SCC, squamous cell carcinoma</kwd><kwd>TURBT, transurethral resection of bladder tumour</kwd><kwd>(N)MI, (non-)muscle-invasive</kwd><kwd>EGFR, epidermal growth factor receptor</kwd></kwd-group><kwd-group><title>Keywords</title><kwd>HER2</kwd><kwd>Bladder cancer</kwd><kwd>Transitional</kwd><kwd>Squamous</kwd><kwd>Schistosomiasis</kwd></kwd-group></article-meta><notes><p id="ms005">UROSCIENCE</p></notes></front><body><sec sec-type="intro" id="s0005"><title>Introduction</title><p>Carcinoma of the bladder is a world-wide health problem, and ranks ninth in cancer incidence rates <xref rid="b0005" ref-type="bibr">[1]</xref>. The highest incidence rate of bladder cancer is recorded in Egypt (37.1 per 100,000 males) <xref rid="b0010" ref-type="bibr">[2]</xref>. Analysis of pooled data showed bladder cancer to comprise 30.3% of all cancers, with a male to female ratio of &#x02248;3:1 <xref rid="b0015" ref-type="bibr">[3]</xref>.</p><p>The standard treatment for muscle-invasive (MI) urothelial bladder cancer is radical cystectomy, which is also the final treatment for refractory non-MI (NMI) TCC of the bladder, together with other histological types, including squamous cell carcinoma (SCC), which accounts for &#x02248;40% of bladder cancers in Egypt <xref rid="b0015" ref-type="bibr">[3]</xref>.</p><p>The recurrence rate after cystectomy approaches 50%, indicating that this treatment alone might not be optimal for some patients <xref rid="b0020" ref-type="bibr">[4]</xref>. Targeted therapy is a novel treatment strategy in oncology, targeting specific signalling pathways within the malignant cells, and that might enhance the cytotoxic effect but with fewer adverse events <xref rid="b0025" ref-type="bibr">[5]</xref>.</p><p>The HER2 gene contributes to physiological mechanisms of cell proliferation by intrinsic tyrosine-kinase activity. It is also termed the NEU, EGFR2, or ERBB2 gene, and is one of the members of the epidermal growth factor receptor (EGFR) family, which includes EGFR (or ERBB1), EGFR3 (or HER3/ERBB3) and EGFR4 (or HER4/ERBB4). The overexpression of HER2 was shown in several malignancies, and it is known to affect proliferation, angiogenesis and metastasis of malignant cells <xref rid="b0030" ref-type="bibr">[6]</xref>.</p><p>Overexpression of HER2 has been associated with different types of malignancies <xref rid="b0125" ref-type="bibr">[7]</xref>; it was over-expressed in up to 34% of invasive breast cancers <xref rid="b0040" ref-type="bibr">[8]</xref>, gastric and colonic carcinomas <xref rid="b0045 b0050" ref-type="bibr">[9,10]</xref>, and bladder cancer <xref rid="b0055" ref-type="bibr">[11]</xref>. In bladder cancer HER2 was reported to have one of the highest rates of expression, with up to 34% of the tumours being HER2-positive <xref rid="b0060" ref-type="bibr">[12]</xref>.</p><p>Trastuzumab is a monoclonal antibody which specifically targets HER2 protein by directly binding to an extracelluar protein receptor. Trastuzumab is used to treat both primary and metastatic breast cancer, and was shown to improve survival rates <xref rid="b0065" ref-type="bibr">[13]</xref>. This has led to an evaluation of its efficacy and anti-tumour activity in patients with HER2 expression in bladder cancers.</p><p>Analysing gene amplification and/or increased protein expression of HER2 by various methods has produced different results <xref rid="b0070" ref-type="bibr">[14]</xref>. Most of this controversy appears to have been caused by technical variables associated with the different methods used for detecting HER2 changes, especially the difference between gene amplification and overexpression <xref rid="b0075" ref-type="bibr">[15]</xref>.</p><p>Thus in the present study we evaluated the expression of HER2 protein using both immunohistochemical (IHC) staining and gene amplification by fluorescent <italic>in situ</italic> hybridisation (FISH) in different inflammatory and neoplastic urinary bladder lesions, including both TCC and SCC of the bladder. The effect of schistosomal infestation on HER2 expression in these lesions was also assessed and compared with normal urothelium as a control.</p></sec><sec sec-type="methods" id="s0010"><title>Patients and methods</title><p>This prospective unrandomised study was approved by the institutional review board, and included patients with radiologically diagnosed bladder lesions listed for transurethral resection of bladder tumour (TURBT) in our Department, together with patients listed for cystoscopy for persistent LUTS. Patients with a previous history of bladder neoplasia were excluded. Ten patients who were examined by cystoscopy as a part of their urological evaluation and/or treatment served as a control. The final study included 72 patients (49 men and 23 women, median age 53&#x000a0;years, range 30&#x02013;79). Patients were divided into the control group (10), a group with cystitis (either schistosomal-associated or nonspecific cystitis, 10), a group with SCC (19), and a group with TCC (MI and NMI, 33) (<xref rid="t0010" ref-type="table">Table 1</xref>). All patients with an apparent tumour had TURBT, and cold-cup biopsies were taken from bladder mucosa of patients with LUTS and those in the control group.</p><p>Specimens were fixed in 10% buffered formalin, paraffin-embedded and processed routinely. Haematoxylin and eosin stains were used to evaluate all bladder lesions and to assess the grade and stage of carcinomas according to the international histological classification of urinary bladder tumours proposed by the WHO in 2004.</p><p>The expression of HER2 was evaluated using light microscopy at &#x000d7;400 magnification, and the percentage of the positively stained cells was calculated and scored according to G&#x000e5;rdmark et al. <xref rid="b0080" ref-type="bibr">[16]</xref>, as &#x02018;negative&#x02019; (score 0 or 1, where 0 is no staining or membrane staining in &#x0003c;10% of tumour cells, and 1 is faint/barely perceptible membrane staining in &#x0003e;10% of tumour cells, with cells only stained in part of their membrane), &#x02018;equivocal&#x02019; (score 2, weak to moderate complete membrane staining in &#x0003e;10% of tumour cells) or &#x02018;strongly positive&#x02019; (score 3, strong complete cell membrane staining in &#x0003e;10% of the tumour cells).</p><p>FISH analysis was used on a representative proportion of the tissue, using the Path Vysion kit (Abbott Laboratories. Abbott Park, IL, USA). All samples with positive HER2 protein expression were evaluated using labelled probes for both fluorophores, i.e., Vysis CEP 17 17p11.1-q11.1 Alpha Satellite DNA Spectrum Green, and Vysis LSI HER-2/neu 17q11.2-12 Spectrum Orange.</p><p>Slides were viewed with a fluorescence microscope (BX51 upright, Olympus Corp, Japan), where three areas were identified and in each area 20 nuclei were assessed. Chromosome 17 copy number and HER2 copy number were assessed for each of the 20 nuclei at &#x000d7;1000 magnification. A ratio of chromosome 17 copy number over HER2/neu copy number was obtained from the 60 nuclei.</p><p>HER2/neu was classified based on the value used in breast cancer diagnostics into &#x02018;amplified&#x02019; (Her2/neu/centromere 17 ratio &#x0003e;2.2) &#x02018;not amplified&#x02019; (Her2/neu/centromere 17 ratio &#x0003c;2) or polysomy (more than one chromosome within the nucleus) <xref rid="b0085" ref-type="bibr">[17]</xref>.</p><p>Standard statistics were used for data management and analysis, assessing the relationship between variables using Spearman&#x02019;s correlation coefficient. All tests were two-tailed and considered statistically significant at <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec><sec sec-type="results" id="s0015"><title>Results</title><sec id="s0020"><title>Immunohistochemical studies of HER2 protein</title><p>HER2 protein was not expressed in both the control and the cystitis group (<xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>A&#x000a0;and&#x000a0;B), while there was strong expression in 31% (16/52) malignant cases (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). Schistosomal infestation appeared not to affect the HER2 expression in patients with cystitis.</p><p>There was HER2-positive expression in 27% of patients with TCC (<xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>C&#x000a0;and&#x000a0;D), while 37% of patients with SCC were positive for HER2 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; <xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>E&#x000a0;and&#x000a0;F).</p><p>Schistosomal infestation in patients with TCC was associated with a statistically significantly higher expression of HER2 than in non-schistosomal TCC (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01), and all cases of SCC were associated with schistosomal infestation (<xref rid="t0010" ref-type="table">Table 1</xref>).</p><p>On stratifying TCC according to degree of muscle invasion, HER 2 was equivocally expressed in 23% of Ta tumours, and positively expressed in 43% and 46% of T1 and T2&#x02013;3 tumours, respectively, with a statistically significant increase in the percentage of HER2 protein immunoexpression compared to Ta tumours (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). There was no significant difference in HER2 immunoexpression in different stages of SCC (<xref rid="t0010" ref-type="table">Table 1</xref>).</p><p>High-grade TCC had statistically significantly greater positive HER2 immunoexpression than low-grade tumours (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). There was no significant difference in HER2 expression between low-grade and high-grade malignancy in SCC.</p></sec><sec id="s0025"><title>HER2/neu gene expression using FISH</title><p>All control and cystitis cases with or without schistosomal infestation were negative for HER2 expression. Both TCC and SCC had a statistically significantly greater HER2 expression than control and cystitis cases (both <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01).</p><p>HER2 expression was positive in 33% of TCC (<xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>A&#x000a0;and&#x000a0;B), compared with only 27% positive by IHC staining (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05), and was similar for SCC (<xref rid="f0010" ref-type="fig">Fig. 2</xref>, C and D), with HER2 expression of 37% by IHC staining but 53% by FISH (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01).</p><p>There was positive HER2 expression detected by FISH in 1/13, 3/7 and 7/13 Ta, T1 and T2&#x02013;3 TCC tumours, respectively. All low-grade TCC were negative for HER2 expression using FISH and IHC staining, but there was statistically significantly greater HER2 expression detected using FISH in high-grade TCC.</p></sec></sec><sec sec-type="discussion" id="s0030"><title>Discussion</title><p>In 2010, bladder cancer was responsible for about 170,000 deaths world-wide <xref rid="b0090" ref-type="bibr">[18]</xref>. In the Egyptian population, bladder cancer accounts for 29.8% of all malignant diseases and it is the most common cancer among males, with schistosomal infestation previously being the most important predisposing factor, although currently the incidence of bilharzial-associated bladder cancer is declining <xref rid="b0015" ref-type="bibr">[3]</xref>.</p><p>The behaviour of cancer is now considered to be a genetically controlled process affecting cell physiology and its interaction with the host organism. It is now possible to evaluate these genetic abnormalities, study oncogenes and tumour-suppresser genes, and changes in cellular molecules, using several diagnostic and prognostic markers.</p><p>HER2/neu (c-erb-B2) is an oncogene present on chromosome 17q21, and is a transmembrane protein characterised by an extracellular domain that interacts with various growth factors. It has been shown to be expressed in several malignancies, including lung, stomach and breast adenocarcinoma <xref rid="b0040 b0045 b0050 b0055" ref-type="bibr">[8&#x02013;11]</xref>. The incidence of overexpression of HER2/neu in bladder cancer is one of the highest among all human malignancies, at 9&#x02013;34% of cancers tested <xref rid="b0090" ref-type="bibr">[18]</xref>.</p><p>The success of trastuzumab therapy in patients with breast carcinoma has stimulated interest in exploring its antitumour activity in patients with bladder cancer, although there is controversy about the value of HER2 expression in these patients <xref rid="b0055 b0060" ref-type="bibr">[11,12]</xref>. Early studies showed increased HER2 expression and with both higher tumour stage and grade. Others suggested that the overexpression of HER2 was an independent variable in determining patient survival <xref rid="b0095" ref-type="bibr">[19]</xref>. HER2 overexpression was evaluated using IHC, FISH and blood analysis. Trastuzumab therapy in patients with breast cancer requires candidates to show either 3+ overexpression by IHC or 2+ overexpression by IHC with positive FISH results <xref rid="b0100" ref-type="bibr">[20]</xref>.</p><p>Schistosomal infestation is considered to be one of the predisposing factors for the development of urinary bladder cancer. Bladder cancers diagnosed in areas of endemic schistosomiasis are usually SCCs, but it appears that the histopathology of bladder cancer in these areas is changing. In a recent study of schistosomiasis-associated bladder cancer conducted in Egypt, the proportion of TCC increased over time <xref rid="b0105" ref-type="bibr">[21]</xref>.</p><p>In the present study HER2 was not identified in benign and inflammatory urothelium by both IHC staining and FISH. Schistosomal infestation seemed not to affect the gene expression. HER2 expression by IHC staining was positive in 30% of all malignant cases, 27% of TCCs, and 37% of SCCs, as was found by Abd-El-moneim et al. <xref rid="b0130" ref-type="bibr">[22]</xref>.</p><p>Positive HER2 expression was statistically significantly greater in high-stage/grade TCC tumours than in low-stage/grade tumours; this is in accord with the results of Hansel et al. <xref rid="b0115" ref-type="bibr">[23]</xref>, who found over-expression of HER2 protein in invasive metastatic disease.</p><p>Using FISH, 40% of all malignant cases were positive for HER2 expression, as were 33% of TCCs and 52% of SCCs. Our results consolidate those of Fleischmann et al. <xref rid="b0120" ref-type="bibr">[24]</xref>, who concluded that for better patient selection, the FISH technique is more accurate than IHC staining.</p><p>The present study has several limitations; it included only a few controls and patients with cystitis, the metastatic status of the patients was not recorded, and the effect of the previous use of intravesical installation (e.g., BCG) in patients with NMI TCC on HER2 expression was not considered.</p><p>In conclusion, HER2 protein is expressed in a subset of patients with bladder cancer who appeared to have a more aggressive disease than those having HER2-negative tumours, and who might be candidates for anti-HER2-targeted therapy as is already used in other malignancies. FISH has a higher detection rate for HER2-positive tumour than does IHC staining.</p></sec><sec id="s0035"><title>Conflict of interest</title><p>None.</p></sec><sec id="s0040"><title>Source of funding</title><p>None.</p></sec></body><back><ref-list><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Naishadham</surname><given-names>D.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2013</article-title><source>CA Cancer J Clin</source><volume>63</volume><year>2013</year><fpage>11</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">23335087</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>D.M.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Pisani</surname><given-names>P.</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><volume>55</volume><year>2005</year><fpage>74</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">15761078</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Gouda</surname><given-names>I.</given-names></name><name><surname>Mokhtar</surname><given-names>N.</given-names></name><name><surname>Bilal</surname><given-names>D.</given-names></name><name><surname>El-Bolkainy</surname><given-names>T.</given-names></name><name><surname>El-Bolkainy</surname><given-names>N.</given-names></name></person-group><article-title>Bilharziasis and bladder cancer: a time trend analysis of 9843 patients</article-title><source>J Egypt Natl Canc Inst</source><volume>19</volume><year>2007</year><fpage>158</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">19034337</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Gendy</surname><given-names>H.</given-names></name><name><surname>Madkour</surname><given-names>B.</given-names></name><name><surname>Abdelaty</surname><given-names>S.</given-names></name><name><surname>Essawy</surname><given-names>F.</given-names></name><name><surname>Khattab</surname><given-names>D.</given-names></name><name><surname>Hammam</surname><given-names>O.</given-names></name></person-group><article-title>Diagnostic and prognostic significance of serum and tissue galectin 3 expression in patients with carcinoma of the bladder</article-title><source>Curr Urol</source><volume>7</volume><year>2013</year><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">26195948</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Balar</surname><given-names>A.</given-names></name><name><surname>Matthew</surname><given-names>V.</given-names></name><name><surname>Milowsky</surname><given-names>I.</given-names></name></person-group><article-title>Cytotoxic and DNA targeted therapy in urothelial cancer: have we squeezed the lemon enough?</article-title><source>Cancer</source><year>2014</year></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>W&#x000fc;lfing</surname><given-names>C.</given-names></name><name><surname>von Struensee</surname><given-names>D.</given-names></name><name><surname>Bierer</surname><given-names>S.</given-names></name><name><surname>B&#x000f6;gemann</surname><given-names>M.</given-names></name><name><surname>Hertle</surname><given-names>L.</given-names></name><name><surname>Eltze</surname><given-names>E.</given-names></name></person-group><article-title>Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy</article-title><source>Aktuelle Urol</source><volume>36</volume><year>2005</year><fpage>423</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">16163605</pub-id></element-citation></ref><ref id="b0125"><label>7</label><element-citation publication-type="book" id="h0125"><person-group person-group-type="editor"><name><surname>Ramzi</surname><given-names>C.</given-names></name><name><surname>Vinay</surname><given-names>K.</given-names></name><name><surname>Stanley</surname><given-names>L.R.</given-names></name></person-group><source>Robbins pathologic basis of disease</source><year>2000</year><publisher-name>WB Saunders</publisher-name><publisher-loc>Philadelphia</publisher-loc><comment>p. 994&#x02013;1004</comment></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Kaptain</surname><given-names>S.</given-names></name><name><surname>Tan</surname><given-names>L.K.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>Her2 and breast cancer</article-title><source>Diagon Mol Path</source><volume>10</volume><year>2001</year><fpage>139</fpage><lpage>152</lpage></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Gravalos</surname><given-names>C.</given-names></name><name><surname>Jimeno</surname><given-names>A.</given-names></name></person-group><article-title>Her2 in gastric cancer, a new prognostic factor and a novel therapeutic target</article-title><source>Ann Oncol</source><volume>10</volume><year>2008</year><fpage>1093</fpage><lpage>1100</lpage></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Schuell</surname><given-names>B.</given-names></name><name><surname>Gruenbergger</surname><given-names>T.</given-names></name><name><surname>Scheithauer</surname><given-names>W.</given-names></name></person-group><article-title>Her2 protein expression in colorectal cancer</article-title><source>BMC Cancer</source><volume>8</volume><year>2006</year><fpage>123</fpage><pub-id pub-id-type="pmid">16681853</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Eltze</surname><given-names>E.</given-names></name><name><surname>Wulfing</surname><given-names>C.</given-names></name><name><surname>Von Struensee</surname><given-names>D.</given-names></name><name><surname>Piechota</surname><given-names>H.</given-names></name></person-group><article-title>Cox2 and Her2 co-expression in invasive bladder cancer</article-title><source>Int J Oncol</source><volume>26</volume><year>2005</year><fpage>1525</fpage><lpage>1531</lpage><pub-id pub-id-type="pmid">15870865</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K.</given-names></name><name><surname>Moriyama</surname><given-names>M.</given-names></name><name><surname>Mori</surname><given-names>S.</given-names></name><name><surname>Saito</surname><given-names>M.</given-names></name><name><surname>Watanuki</surname><given-names>T.</given-names></name><name><surname>Terada</surname><given-names>K.</given-names></name></person-group><article-title>An immunohistologic evaluation of cerbB-2 gene product in patients with urinary bladder carcinoma</article-title><source>Cancer</source><volume>15</volume><year>1992</year><fpage>2493</fpage><lpage>2498</lpage><pub-id pub-id-type="pmid">1358427</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>D.S.</given-names></name><name><surname>Shipley</surname><given-names>W.U.</given-names></name><name><surname>Feldma</surname><given-names>A.S.</given-names></name></person-group><article-title>Bladder cancer</article-title><source>Lancet</source><volume>374</volume><year>2008</year><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">19520422</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>J.S.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Gay</surname><given-names>L.M.</given-names></name><name><surname>Al-Rohil</surname><given-names>R.N.</given-names></name><name><surname>Nazeer</surname><given-names>T.</given-names></name><name><surname>Sheehan</surname><given-names>C.E.</given-names></name></person-group><article-title>A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma</article-title><source>Clin Cancer Res</source><volume>20</volume><year>2014</year><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">24192927</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Latif</surname><given-names>Z.</given-names></name><name><surname>Watters</surname><given-names>A.D.</given-names></name><name><surname>Dunn</surname><given-names>I.</given-names></name><name><surname>Grigor</surname><given-names>K.M.</given-names></name><name><surname>Underwood</surname><given-names>M.A.</given-names></name><name><surname>Bartlett</surname><given-names>J.M.</given-names></name></person-group><article-title>HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder</article-title><source>Br J Cancer</source><volume>89</volume><year>2003</year><fpage>1305</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">14520464</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>G&#x000e5;rdmark</surname><given-names>T.</given-names></name><name><surname>Wester</surname><given-names>K.</given-names></name><name><surname>De la Torre</surname><given-names>M.</given-names></name><name><surname>Carlsson</surname><given-names>J.</given-names></name><name><surname>Malmstr&#x000f6;m</surname><given-names>P.U.</given-names></name></person-group><article-title>Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases</article-title><source>BJU Int</source><volume>95</volume><year>2005</year><fpage>982</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">15839918</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Coombs</surname><given-names>L.M.</given-names></name><name><surname>Pigott</surname><given-names>D.A.</given-names></name><name><surname>Sweeney</surname><given-names>E.</given-names></name><name><surname>Proctor</surname><given-names>A.J.</given-names></name><name><surname>Eydmann</surname><given-names>M.E.</given-names></name><name><surname>Parkinson</surname><given-names>C.</given-names></name></person-group><article-title>Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder</article-title><source>Br J Cancer</source><volume>63</volume><year>1991</year><fpage>601</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">1673627</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Center</surname><given-names>M.M.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Ward</surname><given-names>E.</given-names></name><name><surname>Forman</surname><given-names>D.</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><volume>61</volume><year>2011</year><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">21296855</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Gandour-Edwards</surname><given-names>R.</given-names></name><name><surname>Lara</surname><given-names>P.N.</given-names><suffix>Jr</suffix></name><name><surname>Folkins</surname><given-names>A.K.</given-names></name><name><surname>LaSalle</surname><given-names>J.M.</given-names></name><name><surname>Beckett</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?</article-title><source>Cancer</source><volume>95</volume><year>2002</year><fpage>1009</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">12209684</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>M.A.</given-names></name><name><surname>Horten</surname><given-names>B.C.</given-names></name><name><surname>Da Silva</surname><given-names>M.M.</given-names></name></person-group><article-title>HER2 Amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues</article-title><source>Lancet</source><volume>376</volume><year>2010</year><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">20728210</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>H.K.</given-names></name><name><surname>Mahfouz</surname><given-names>S.</given-names></name></person-group><article-title>Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade</article-title><source>Urology</source><volume>79</volume><year>2012</year><fpage>379</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">22112287</pub-id></element-citation></ref><ref id="b0130"><label>22</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Abd El-Moneim</surname><given-names>H.M.</given-names></name><name><surname>Tawfik</surname><given-names>H.M.</given-names></name><name><surname>El-Sherbiny</surname><given-names>Y.M.</given-names></name><name><surname>Twafik</surname><given-names>E.R.</given-names></name></person-group><article-title>Analysis of Her2/neu overexpression and amplification in urothelial carcinoma of the bladder associated with cox-2 overexpression</article-title><source>Int J Cancer Res</source><volume>7</volume><year>2011</year><fpage>8</fpage><lpage>24</lpage></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>D.E.</given-names></name><name><surname>Swain</surname><given-names>E.</given-names></name><name><surname>Dreicer</surname><given-names>R.</given-names></name><name><surname>Tubbs</surname><given-names>R.R.</given-names></name></person-group><article-title>HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases</article-title><source>Am J Clin Pathol</source><volume>130</volume><year>2008</year><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">18628098</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Fleischmann</surname><given-names>A.</given-names></name><name><surname>Rotzer</surname><given-names>D.</given-names></name><name><surname>Seiler</surname><given-names>R.</given-names></name><name><surname>Studer</surname><given-names>U.E.</given-names></name><name><surname>Thalmann</surname><given-names>G.N.</given-names></name></person-group><article-title>Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours</article-title><source>Eur Urol</source><volume>60</volume><year>2011</year><fpage>350</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">21640482</pub-id></element-citation></ref></ref-list><fn-group><fn id="d32e451"><p>Peer review under responsibility of Arab Association of Urology.</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Figure 1</label><caption><p>IHC staining of the study group tissues. (A) A control showing negative HER2 protein, scoring 1+ in the urothelial lining. (B) A case of polypod cystitis showing negative HER2 protein immunoexpression, score 2+, IHC, Her2, DAB, &#x000d7;200. (C) A case of poorly differentiated urothelial TCC, showing equivocal HER2 protein immunoexpression in &#x0003e;30% of tumour cells; IHC, Her2, DAB, &#x000d7;400. (D) A case of papillary urothelial carcinoma showing strong HER2 protein immunoexpression, score 3+ in &#x0003e;70% of cells; IHC, Her2, DAB, &#x000d7;200. (E) A case of moderately differentiated schistosomal-associated SCC, strongly positive for HER2 protein, score 3+; IHC, Her2, DAB, &#x000d7;400. (F) A case of moderately differentiated SCC, grade II, showing negative HER2 protein immunoexpression, score 1+, IHC, Her2, DAB, &#x000d7;200.</p></caption><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Figure 2</label><caption><p>HER2 amplification by FISH. (A) Papillary urothelial TCC, negative for HER2 gene amplification. (B) Urothelial TCC, positive for HER2 gene amplification, showing red clusters. (C) Bilharzial SCC, negative for HER2 gene amplification. (D) SCC, positive for HER2 gene amplification, showing &#x0003e;6 red signals per cell. All &#x000d7;60.</p></caption><graphic xlink:href="gr2"/></fig><table-wrap id="t0010" position="float"><label>Table 1</label><caption><p>The clinico-pathological distribution in the various groups, and the HER2 protein and gene immunoexpression by IHC and HER2 gene expression using FISH.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group</th><th><italic>N</italic></th><th>M/F</th><th colspan="3">HER2 by IHC (score), <italic>n</italic> or <italic>n</italic> (%)<hr/></th><th colspan="3">HER2 by FISH, <italic>n</italic> or <italic>n</italic> (%)<hr/></th></tr><tr><th>Negative (0/1+)</th><th>Equivocal (2+)</th><th>Strongly positive (3+)</th><th>Not amplified</th><th>Polysomy</th><th>Amplified</th></tr></thead><tbody><tr><td>Control</td><td>10</td><td>8/2</td><td>10</td><td>0</td><td>0</td><td>10</td><td>0</td><td>0</td></tr><tr><td>Cystitis</td><td>10</td><td>6/4</td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Bilharzial</td><td>6</td><td/><td>6</td><td>0</td><td>0</td><td>6</td><td>0</td><td>0</td></tr><tr><td>&#x000a0;Not bilharzial</td><td>4</td><td/><td>4</td><td>0</td><td>0</td><td>4</td><td>0</td><td>0</td></tr><tr><td colspan="9">&#x02028;&#x02028;</td></tr><tr><td>SCC</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Bilharzial</td><td>19</td><td>12/7</td><td>9 (47)</td><td>3 (16)</td><td>7 (37)</td><td>7 (37)</td><td>2 (11)</td><td>10 (53)<xref rid="tblfn1" ref-type="table-fn">a</xref></td></tr><tr><td>&#x000a0;Not bilharzial</td><td>0</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="9">&#x02028;&#x02028;</td></tr><tr><td>TCC</td><td>33</td><td>23/10</td><td>13 (39)</td><td>11 (33)</td><td>9 (27)</td><td>20 (61)</td><td>2 (6)</td><td>11 (33)<xref rid="tblfn3" ref-type="table-fn">c</xref></td></tr><tr><td>&#x000a0;Ta</td><td>13</td><td/><td>10</td><td>3</td><td>0</td><td>12</td><td>0</td><td>1<xref rid="tblfn2" ref-type="table-fn">b</xref></td></tr><tr><td>&#x000a0;T1</td><td>7</td><td/><td>0</td><td>4</td><td>3</td><td>3<xref rid="tblfn4" ref-type="table-fn">d</xref></td><td>1</td><td>3</td></tr><tr><td>&#x000a0;T2&#x02013;3</td><td>13</td><td/><td>3</td><td>4</td><td>6</td><td>5</td><td>1</td><td>7<xref rid="tblfn5" ref-type="table-fn">e</xref></td></tr><tr><td>&#x000a0;Low-grade</td><td>9</td><td/><td>6</td><td>3</td><td>0</td><td>8</td><td>1</td><td>0</td></tr><tr><td>&#x000a0;High-grade</td><td>24</td><td/><td>7 (29)</td><td>8 (33)</td><td>9 (38)</td><td>12 (50)</td><td>1 (4)</td><td>11 (46)<xref rid="tblfn6" ref-type="table-fn">f</xref></td></tr><tr><td>&#x000a0;Bilharzial</td><td>16</td><td/><td>9 (56)</td><td>2 (13)</td><td>5 (31)</td><td>10 (63)</td><td>1 (6)</td><td>5 (31)</td></tr><tr><td>&#x000a0;Not bilharzial</td><td>17</td><td/><td>4 (24)</td><td>9 (53)</td><td>4 (24)</td><td>10 (63)</td><td>1 (6)</td><td>6 (35)<xref rid="tblfn7" ref-type="table-fn">g</xref></td></tr></tbody></table><table-wrap-foot><fn><p>FISH vs. IHC.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn1"><label>a</label><p><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, positive HER2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn2"><label>b</label><p><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, positive HER2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn3"><label>c</label><p><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, positive HER2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn4"><label>d</label><p><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.1, negative HER2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn5"><label>e</label><p><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, positive HER2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn6"><label>f</label><p><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, positive HER2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn7"><label>g</label><p><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, positive HER2.</p></fn></table-wrap-foot></table-wrap></floats-group></article>